14 research outputs found
Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy
Nurse-Led Vital Signs Monitoring Can Safely Identify Low-Risk Hematology-Oncology Patients For De-Escalation
Evaluation of lifestyle risk factor differences in global patterns of breast cancer mortality and DALYs during 1990–2017 using hierarchical age-period-cohort analysis
Young age increases the risk for lymph node metastasis in patients with early Colon Cancer
Inevitable nonunion after ulnar shortening osteotomy in patients with ulnar impaction syndrome and breast cancer under bisphosphonate treatment
Progress in adjuvant systemic therapy for breast cancer
The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first adjuvant endocrine therapy and chemotherapy trials, continuous improvements of clinical outcomes have been achieved through intense therapeutic escalation, albeit with increased health-care costs and treatment-related toxicities. In contrast to the advances achieved in surgery or radiotherapy, the identification of the patient subgroups that will derive clinical benefit from therapeutic escalation has proved to be a daunting process hindered by a lack of collaboration between scientific groups and by the pace of drug development. In the past few decades, initiatives towards de-escalation of systemic adjuvant treatment have achieved success. Herein, we summarize attempts to escalate and de-escalate adjuvant systemic treatment for patients with breast cancer and argue that new, creative trial designs focused on patients’ actual needs rather than on maximizing drug market size are needed. Ultimately, the adoption of effective treatments that do not needlessly expose patients and health-care systems to harm demands extensive international collaboration between academic groups, governments, and pharmaceutical companies.SCOPUS: re.jDecretOANoAutActifinfo:eu-repo/semantics/publishe